SP Industries Acquires Bel-Art Products
News Jul 02, 2014
SP Industries, Inc. (SP) has announced that it has acquired privately held Bel-Art Products (Bel-Art). Headquartered in Wayne (NJ, USA), Bel-Art is a global provider of innovative laboratory solutions serving the scientific, industrial, and healthcare end markets.
“The acquisition of best-in-class companies that complement our existing product lines and allow us to expand our presence in the global market has proven to be a very effective strategy,” stated SP Industries CEO, Bill Downs. Downs continued by saying, “Bel-Art Products, which will continue operating under its own name, has done a superb job of building brand equity, developing a robust stream of innovative new products, and working with its channel partners to effectively serve the market. We are excited at the increased opportunities to grow market share and will cross-market across brands and leverage each organization’s expertise in product development, operations, finance, and supply chain management.”
Brad Mahood, Chief Operating Officer of Bel-Art, will play a key leadership role in sales, marketing, and product management at the corporate level. Additionally, David Landsberger, President of Bel-Art Products, will join the Board of Directors for SP Industries.
Compound Offers Pain-relief of Opioids Without Addictive PropertiesNews
Researchers have engineered a new compound that animal tests suggest could offer the pain-relieving properties of opioids such as morphine and oxycodone without the risk of addiction.READ MORE
Compound Selectively Kills Liver Cancer Stem CellsNews
Acyclic retinoid, an artificial compound derived from vitamin A, has been found to prevent the recurrence of hepatocellular carcinoma (HCC), the most common form of liver cancer.READ MORE
170 Potential Lung Cancer Drug Targets Identified Using Unique Cellular LibraryNews
After testing more than 200,000 chemical compounds, UT Southwestern’s Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Structural and Molecular Biology 2018
Aug 22 - Aug 23, 2018
Asia Pacific Congress on Probiotics, Prebiotics and Nutrition
Oct 15 - Oct 16, 2018